Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy

American Journal of Nephrology

Volumn 24, Issue 1, 2004, Pages 32-40

  Bolton, W Kline ^a,l   Cattran, Daniel C ^b   Williams, Mark E ^c   Adler, Sharon G ^d   Appel, Gerald B ^e   Cartwright, Kenneth ^f   Foiles, Peter G ^f   Freedman, Barry I ^g   Raskin, Philip ^h   Ratner, Robert E ⁱ   Spinowitz, Bruce S ^j   Whittier, Frederick C ^k   Wuerth, Jean Paul ^f  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Columbia Univ Coll Phys Surgs ^*  (United States)

^f Alteon Inc   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ MEDSTAR RESEARCH INSTITUTE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Advanced glycation end product inhibition; Diabetic nephropathy; Diabetic retinopathy; Pimagedine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; AUTOANTIBODY; CREATININE; LIVER ENZYME; PLACEBO;

ADULT; ANEMIA; ARTICLE; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMATOPOIETIC SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINOPATHY; SCORING SYSTEM; SIDE EFFECT; URINARY EXCRETION; UROGENITAL TRACT DISEASE;

ADULT; ALBUMINURIA; BLOOD PRESSURE DETERMINATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 10744223527     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075627     Document Type: Article

References (26)

1. US Renal Data Systems: USRDS 1999 Annual Data Report. Bethesda, National Institutes of Health, 1999.
2. Brownlee M: The pathological implications of protein glycation. Clin Invest Med 1995;18:275-281.
3. Vlassara H: Protein glycation in the kidney: Role in diabetes and aging. Kidney Int 1996;49:1795-1804.
4. Berg T, Clausen J, Torjesen P, Dahl-Jorgensen K, Bangstad H, Hanssen K: The advanced glycation end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1997;21:1997-2002.
5. Berg T, Bangstad H, Torjesen P, Osterby R, Bucala R, Hanssen K: Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997;46:661-665.
6. Beisswenger P, Makita Z, Curphey T, et al: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824-829.
7. Li Y, Steffes MW, Donnelly T, et al: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996;93:3902-3907.
8. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995;26:875-888.
9. Friedman EA, Distant DA, Fleishhacker JF, Boyd TA, Cartwright K: Aminoguanidine prolongs survival in azotemic-induced diabetic rats. Am J Kidney Dis 1997;30:253-259.
10. Cockcroft DS, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
11. American Diabetes Association: Clinical Practice Recommendations. Diabetes Care 1999;22(suppl):S1-S114.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
13. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002;39 (suppl):S1-S266.
14. Bolton WK, Kliger AS: Chronic renal insufficiency: Current understandings and their implications. Am J Kidney Dis 2000;36(6 Suppl 3):S4-S12.
15. Makino H, Shikata K, Hironaka K, et al: Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995;48:517-526.
16. Horie K, Miyata T, Maeda K, et al: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: Implications of glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997;100:2995-3004.
17. Makino H, Shikata K, Kushiro M, et al: Role of advanced glycation end-products in the progression of diabetic nephropathy. Nephrol Dial Transplant 1996;11(Suppl 5):76-80.
18. Vlassara H, Striker L, Teichberg S, Fuh H, Li Y, Steffes MW: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708.
19. Wright JT Jr, Bakris G, Greene T, et al for the African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK Trial. JAMA 2002;288:2421-2431.
20. Agodoa LY, Appel L, Bakris GI, et al for the African American Study of Kidney Disease and Hypertension Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001;285:2719-2728.
21. Lewis EJ, Hunsicker LG, Clarke WR, et al for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
22. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-1010.
23. Cerami C, Founds H, Nicholl I, et al: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997;94:13915-13920.
24. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-986.
25. Torffvit O, Thysell H, Nassberger L: Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hum Exp Toxicol 1994;13:563-567.
26. Mason P, Lockwood CM: Rapidly progressive nephritis in patients taking hydralazine. J Clin Lab Immunol 1986;20:151-153.